Iconovo AB (publ) (STO:ICO)
1.200
-0.045 (-3.61%)
Nov 4, 2026, 5:25 PM CET
Iconovo AB Earnings Call Transcripts
Fiscal Year 2026
-
Revised summary: The company is shifting from a tech platform to monetizing a diverse pipeline of inhaled medicines, including generics and biologics. Regulatory changes and a patent cliff offer market opportunities. Key projects are in licensing and preclinical stages, with partnerships and funding supporting full pharma operations and long-term value.